A Phase 4, Double Blind, Randomized, Placebo Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis. The COBALT Study Clinical Outcomes with OBeticholic Acid in Liver Treatment (COBALT)
Phase of Trial: Phase IV
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Primary biliary cirrhosis
- Focus Registrational; Therapeutic Use
- Acronyms COBALT
- Sponsors Intercept Pharmaceuticals
- 19 Jun 2017 Phase of the trial has been changed from Phase III to Phase IV, Planned number of patients changed from 350 to 428, time frame for primary endpoint changed from 8 years to 10 years.
- 19 Jun 2017 Planned End Date changed from 1 Apr 2023 to 1 Apr 2025.
- 19 Jun 2017 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History